Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03517488 · ClinicalTrials.gov registry record · Phase 1
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
A Phase 1 study of Melanoma and Hepatocellular Carcinoma, sponsored by Xencor.
- Completed
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 17
- Study locations
NCT03517488 is a Phase 1 study of Melanoma and Hepatocellular Carcinoma that has completed, run by Xencor. The registered enrollment target is 150 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (79% lower). The trial reports 17 study locations across 12 states.
The verdict
NCT03517488, a Phase 1 study of Melanoma and Hepatocellular Carcinoma, has completed, sponsored by Xencor.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 17
- Study locations
Study Summary
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb20717 in subjects with selected advanced solid tumors.
Conditions Studied
Interventions
- BIOLOGICAL XmAb20717
Study Locations (17)
California
- Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute - Los Angeles
- UCLA Hematology-Oncology Clinic (Westwood) - Los Angeles
- University of California San Diego Moores Cancer Center - San Diego
- University of California San Francisco Medical Center - San Francisco
New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone - New York
- Columbia University Medical Center - Herbert Irving Pavilion - New York
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
- UPMC Hillman Cancer Center - Pittsburgh
Georgia
- Emory University - Atlanta
Illinois
- University of Chicago Medicine - Chicago
Kansas
- The University of Kansas Clinical Research Center - Fairway
Michigan
- Karmanos Cancer Institute - Detroit
Oregon
- Providence Portland Medical Center - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2018-07-10 |
| Est. Completion | 2022-09-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03517488
The ClinicalTrials.gov registry entry for NCT03517488 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (79% lower). The listed sponsor is Xencor, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which XmAb20717 is the first listed.
NCT03517488 reports 17 study locations spanning 12 distinct geographic areas - top geographies include California, New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03517488 about?
NCT03517488 is a clinical study titled "A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors". This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb20717 in subjects with selected advanced solid tumors.
What is the current status of trial NCT03517488?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2018-07-10. Estimated completion is 2022-09-06.
What conditions does trial NCT03517488 study?
This clinical trial studies the following conditions: Melanoma, Hepatocellular Carcinoma, Renal Cell Carcinoma, Breast Carcinoma, Urothelial Carcinoma.
What interventions are being tested in trial NCT03517488?
The interventions under investigation include: XmAb20717 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03517488?
This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03517488 being conducted?
This trial has 17 study locations across California, Georgia, Illinois, Kansas, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.